A biological age score derived from four common blood markers—chronological age, creatinine, blood glucose, and C-reactive protein (CRP)—successfully predicted future cognitive impairment in middle-aged and older adults, according to a study published in Scientific Reports. Researchers found that this “light BioAge” index provides a more nuanced look at cognitive risk than age alone, offering a … Read more
Eli Lilly reported second-quarter revenue of $23 billion, a 48% increase year over year, driven by soaring demand for its GLP-1 medications Mounjaro and Zepbound, according to the company’s earnings report. The pharmaceutical giant subsequently raised its annual revenue guidance to a range between $85 billion and $87 billion, pushing its stock price up nearly … Read more
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), triggers rapid but largely reversible shifts in the gut microbiome of obese mice, according to a study published in the journal Microbiology Spectrum. Researchers found that while the drug alters bacterial community structure during active treatment, these changes largely normalize within seven days of discontinuing the medication. … Read more
Daily consumption of raw tomatoes and tomato sauce significantly reduces controlled attenuation parameter (CAP)-defined hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease (MASLD), according to an exploratory randomized controlled trial published in the journal Nutrients. Researchers found that a six-week tomato-rich diet outperformed a tomato-free control group, dropping median CAP values by 35 … Read more
Traditional Japanese medicine Bofutsushosan, widely used to treat obesity, may also protect aging tissues from destructive fibrosis, according to a preclinical study published in Phytomedicine. Researchers at the University of Osaka and Kobayashi Pharmaceutical Co., Ltd. found that the multi-ingredient formula reduced scar-like tissue buildup in the liver and fat tissue of mice fed a … Read more
Calocurb, a New Zealand-based company, has announced findings from a new clinical study published in the US medical journal Obesity Pillars. According to the brand, the research demonstrates that its 100% natural GLP-1 activator effectively promotes weight loss while preserving muscle mass during six months of consistent use paired with a healthy diet and exercise. … Read more
A study published in the journal Nutrients has linked high consumption of ultra-processed foods (UPFs) to early, measurable changes in insulin secretion and sensitivity among nondiabetic children. Researchers analyzed data from the San Antonio Family Assessment of Metabolic Risk Indicators in Youth (SAFARI) study, finding that higher UPF intake correlates with markers of insulin resistance … Read more
A recent cross-sectional study published in the journal Nutrients found no statistically significant link between an individual’s chronotype—their natural preference for morning or evening activity—and the presence of liver fat or fibrosis in adults with overweight or obesity. Researchers at the National Institute of Gastroenterology in Italy assessed 119 medication-naïve participants using the Morningness–Eveningness Questionnaire … Read more
The European Commission recently approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity, according to Novo Nordisk. This regulatory milestone makes Wegovy the first GLP-1 tablet authorized for weight management in the European Union, following previous approvals in the United States, United Kingdom, United Arab … Read more
The prevalence of GLP-1 drugs for weight loss among U.S. adults has reached a record high, with 11% of the population currently using medications like Ozempic and Wegovy, according to a Gallup survey of 5,065 adults conducted between May 28 and June 5. This surge correlates with a decline in the national obesity rate, which … Read more